Supports investigator-initiated clinical trials (Phase 0–IV) in cancer prevention and control—spanning early detection, screening, prevention/interception, healthcare delivery, quality of life, supportive/palliative care, and survivorship—to generate evidence that can change clinical practice and/or public health. Diagnosis/oncologic treatment efficacy trials are out of scope.
Eligibility criteria:
-
Eligible applicants include U.S. and non-U.S. organizations; foreign institutions and foreign components are allowed.
-
PD/PI must have an eRA Commons ID; Multiple PD/PI (MPI) permitted.
-
Application must meet the NIH definition of a clinical trial and include required clinical trial materials.
-
Not responsive: trials testing oncologic treatments or diagnostic imaging efficacy; Phase 0–II oncologic interventional or imaging trials covered under PAR-25-081.
-
If requesting ≥$500,000 in direct costs in any year (excl. consortium F&A), contact NCI program staff ≥8 weeks before submission.
Funding details:
-
Project period: up to 5 years.
-
Budget: no cap; must reflect actual project needs.
Deadlines:
-
Oct 05, 2025, Feb 05, 2026, Jun 05, 2026, Oct 05, 2026.
Where to go for further information:
-
Program details (PAR-25-167).
-
Cancer prevention/early detection/symptom management trials: Goli Samimi, PhD, MPH — [email protected].
-
Cancer control & population sciences trials: Tanya Agurs-Collins, PhD, RD — [email protected].